BIO survey to elucidate US biopharma’s reliance on Chinese CDMOs amid decoupling threats
Fierce Pharma
MAY 1, 2024
biopharma companies rely on Chinese contractors to provide lab research and drug manufacturing services. It’s no secret that U.S. Facing a push for China-U.S. decoupling from Washington, the industry trade group BIO now wants to quantify the U.S.’s s dependence on Chinese CDMOs through a survey.
Let's personalize your content